Curt Columbus, Artistic Director of Trinity Rep, to Step Down Next Fall After 20 Years

Columbus has served as the Providence theater company’s artistic director since 2006

The Trinity Repertory Company is based at the Lederer Theater Center in downtown Providence.
The Trinity Repertory Company is based at the Lederer Theater Center in downtown Providence.
Courtesy Trinity Repertory Company
Share
The Trinity Repertory Company is based at the Lederer Theater Center in downtown Providence.
The Trinity Repertory Company is based at the Lederer Theater Center in downtown Providence.
Courtesy Trinity Repertory Company
Curt Columbus, Artistic Director of Trinity Rep, to Step Down Next Fall After 20 Years
Copy

The longtime artistic director of Providence’s Trinity Repertory theater company plans to step down next fall, the theater company announced Wednesday.

Curt Columbus has led the theater group since 2006, directing more than 25 productions. He is also a playwright.

In a statement, Columbus said it is “time for new adventures, for me and for Trinity Repertory Company.”

“I firmly believe that every artistic endeavor needs renewal and revitalization,” Columbus said. “While I could stay at Trinity Rep forever, the health of the theater and its artistry depends upon this kind of change.”

Trinity Rep says it is conducting a national search for a new artistic director.

Founded in 1963, Trinity Rep’s annual production of A Christmas Carol is a holiday mainstay in Rhode Island’s arts scene. The company produces several plays each season, including new works, and it received the Tony Award for Outstanding Regional Theater in 1981.

Health officials say an East Providence mosquito tested positive for West Nile Virus, urging residents to use repellent and eliminate standing water as mosquito season ramps up.
Rhode Island Attorney General Peter Neronha says new funding plans aim to resolve a multimillion-dollar gap and secure the future of the long-struggling CharterCARE hospitals
The Woonsocket-based health care giant reported $98.9 billion in revenue, boosted by higher prescription volume and a 39% jump in health insurance income, sending shares up 8% in premarket trading